NCT06310473View on ClinicalTrials.gov

Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2028

Conditions
Gastric CancerEsophagogastric Junction Cancer
Interventions
DRUG

Cadonilimab

10mg/kg intravenous (IV) every 3 weeks ;

DRUG

Oxaliplatin

130mg/m², iv drip for 2h, d1, q3w;

DRUG

Capecitabine

1000mg/m² po, Bid, d1-14, q3w ;

Trial Locations (1)

510-515

Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
lead

Nanfang Hospital, Southern Medical University

OTHER

NCT06310473 - Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial | Biotech Hunter | Biotech Hunter